# The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Source: https://onco.cc/trials/nct04233346/  
OnCo record `nct04233346` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ponatinib in chronic myeloid leukaemia and acute lymphoblastic leukaemia, run by Otsuka Beijing Research Institute, active and no longer recruiting.

## Summary

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation is a phase 2 interventional study registered as NCT04233346 by Otsuka Beijing Research Institute, with 93 participants enrolled, started 2020-07-09 and due to reach its primary completion in 2022-07-22. Interventions recorded: Ponatinib 30mg OD and Ponatinib 45mg OD.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04233346
- Phase: 2
- Setting: A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
- Sponsor: Otsuka Beijing Research Institute
- Enrolled: 93

## Sources

- ClinicalTrials.gov NCT04233346: https://clinicaltrials.gov/study/NCT04233346

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- drugs: [Ponatinib](https://onco.cc/drugs/ponatinib/)

---
JSON: https://onco.cc/api/v1/entities/nct04233346.json